Gemcitabine HCl

For research use only.

Catalog No.S1149 Synonyms: LY188011

63 publications

Gemcitabine HCl Chemical Structure

Molecular Weight(MW): 299.66

Gemcitabine HCl is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.

Size Price Stock Quantity  
USD 57 In stock
USD 70 In stock
USD 210 In stock
USD 497 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Gemcitabine HCl has been cited by 63 publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Gemcitabine HCl is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.
Features Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity.
Targets
DNA synthesis (Capan2 cells) [1] DNA synthesis (BxPC3 cells) [1] DNA synthesis (MIAPaCa2 cells) [1] DNA synthesis (PANC1 cells) [1]
12 nM 18 nM 40 nM 50 nM
In vitro

Gemcitabine induced NF-κB activity in BxPC-3, PANC-1, and MIA PaCa-2 cells and decreased the level of the NF-κB inhibitor IκBα in BxPC-3 and PANC-1 cells. Treatment of BxPC-3 cells with low dose Gemcitabine for 48 hours results in a dose-dependent increase in NF-κB binding. In contrast, NF-κB DNA binding is decreased in BxPC-3 cells treated with the higher Gemcitabine doses for 48 h; however, 24-h treatment with these higher doses increases NF-κB binding in BxPC-3 cells [2]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CCRF-CEM M2XKSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTJwOTFCtUAyNjhibl2= M3XwOFIzPDJ3OEi1
CCRF-CEM/dCK−/− Mon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\OTWM2OD1{NECuOEDDuSB{OT6wJO69VQ>? MYqyNlQzPTh6NR?=
L1210 wt Mn3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXftNo5QUUN3ME2xMlMhyrFiMD6zJI5O MXuyNlQzPTh6NR?=
L1210 10K M{XWcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmC5TWM2OD1{Mj6yJOKyKDNwNzFOwG0> NFy5RVAzOjR{NUi4OS=>
TC-1  MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDIblJKSzVyPUG0MlchyrFiMj64JI5O Mo\XNlI1OjV6OEW=
TC-1-GR NH76R|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTN4LkegxtEhPS5zIN88US=> M1zFdlIzPDJ3OEi1
MIA PaCa-2 M365[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jKRmlEPTB;NEmuO{DDuSBzNz63JI5O MXmyNlQzPTh6NR?=
PANC-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjTTWM2OD1-IESwNEDPxE1? M2LvblIzPDJ3OEi1
CCRF-CEM MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zod2lEPTB;Mj65JOKyKDFwODDuUS=> M3vQTVIzPDJ3OEi1
CCRF-CEM-AraC-8C NF7rVpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TRNGlEPTB;OUm4MlghyrFiOT60JI5O NXjKeo1NOjJ2MkW4PFU>
CCRF-CEM  NVn2eXAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUexR3hpPzJiaB?= MmLiTWM2OD1{LkCgxtEhOC54IH7N NWDUN5RNOjF6NUG4OFM>

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
p70S6K1 / p-S6 / HIF-1α; 

PubMed: 27765914     


Cells were treated with different doses of gemcitabine (0, 1.5 and 2.5 μM), the expression levels of p70S6K1, p-S6 and HIF-1α were determined by Western blotting. GAPDH is used as an internal control. 

LC3-I / LC3-II; 

PubMed: 27384485     


A, E. The levels of LC3-I and LC3-II detected by Western blotting were quantified by densitometry using Image J software. The ratio of LC3-II to LC3-I was evaluated after treated with gemcitabine (MCF-7: 4 μg/ml; MDA-MB-231: 1 μg/ml) for 0 h (control), 12, 24 and 48 h. B, F. The ratio of LC3-II to actin was assayed after treated with gemcitabine, chloroquine (CQ) (MCF-7: 2.5 μM; MDA-MB-231: 5 μM), and gemcitabine plus CQ (added before gemcitabine treatment for 1 h) for indicated time (MCF-7: 48 h; MDA-MB-231: 24 h).

pS-ERα / ERα / pERK / ERK; 

PubMed: 27384485     


MCF-7 and MDA-MB-231 cells were treated by gemcitabine with different concentrations (MCF-7: 0, 2, 4, 8 μg/ml; MDA-MB-231: 0, 0.5, 1, 2 μg/ml), and the phosphorylation of ERα (ser167), ERK (Thr202/Tyr204) and expression of LC3-I and LC3-II were detected.

caspase-3 / caspase-8 / caspase-9; 

PubMed: 16307741     


H1299 and H1299/GR cells were treated with 100 nM gemcitabine for the indicated time periods, and proteins in whole-cell lysates were analyzed by immunoblotting with anti-caspase-3, caspase-8, and caspase-9 antibodies. The arrowheads represent cleavage proteins. β-actin was used as a loading control.

p-JNK / JNK / p-ATF2 / p-c-Jun; 

PubMed: 16307741     


Time-dependent activation of the JNK signaling pathway by gemcitabine treatment. H1299 and H1299/GR cells were treated with 100 nM gemcitabine for the indicated time periods. Cell lysates were then subjected to western blotting using total JNK and phospho-specific antibodies to JNK, c-Jun, and ATF2. Maximal phosphorylation of those molecules is observed in H1299 cells treated with gemcitabine for 48 h.

27765914 27384485 16307741
Immunofluorescence
BMI1; 

PubMed: 27177084     


Gemcitabine enhanced nuclear accumulation of Bmi1 by immunofluorescence staining. 

27177084
Growth inhibition assay
Cell viability ; 

PubMed: 27765914     


A and B. Pancreatic adenocarcinoma cells Bxpc-3 (A) and Panc-1 (B) were treated with gemcitabine (GEM) for 48 h at different doses. The cell viability was analyzed by CCK-8 assay, and normalized to cells without gemcitabine treatment.

27765914
In vivo Intratumoral NF-κB activity is significantly elevated (1.3- to 1.8-fold) in the Gemcitabine-treated mice compared to the PBS-treated mice, suggesting that Gemcitabine also induces NF-κB activation. [2]

Protocol

Cell Research:[2]
- Collapse
  • Cell lines: BxPC-3, MIA PaCa-2, and PANC-1 cells
  • Concentrations: 0.2 μM
  • Incubation Time: 24 hours or 48 hours
  • Method: BxPC-3, MIA PaCa-2, and PANC-1 cells are seeded in a 96-well plate. After 24 hours, cells are treated with vehicle, DMAPT and/or Gemcitabine for an additional 24 hours or 48 hours. Apoptosis is quantified using the Cell Death Detection ELISA to detect the amount of cytoplasmic histone-associated DNA fragments and expressed relative to vehicle-treated cells.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: Athymic nude mice with MIA PaCa-2 cells
  • Dosages: 50 mg/kg or 100 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro Water 19 mg/mL (63.4 mM)
DMSO Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing. 		19mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 299.66
Formula

C9H11F2N3O4.HCI
CAS No. 122111-03-9
Storage powder
in solvent
Synonyms LY188011
Smiles Cl.NC1=NC(=O)N(C=C1)C2OC(CO)C(O)C2(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04383119 Not yet recruiting Drug: Trabectedin|Drug: Gemcitabine Leiomyosarcoma of Ovary|Soft Tissue Sarcoma Italian Sarcoma Group|PharmaMar September 1 2020 Phase 2
NCT04338763 Not yet recruiting Drug: RP72|Drug: Gemcitabine Pancreatic Cancer|Pancreatic Cancer Non-resectable|Pancreatic Cancer Metastatic Rise Biopharmaceuticals Inc.|Amarex Clinical Research April 30 2020 Phase 1
NCT04241276 Not yet recruiting Drug: ATRA|Drug: Gemcitabine|Drug: nab-paclitaxel Pancreatic Cancer Queen Mary University of London|Medical Research Council|Celgene April 30 2020 Phase 2
NCT03773302 Recruiting Drug: BGJ398|Drug: Gemcitabine|Drug: Cisplatin Advanced Cholangiocarcinoma|FGFR2 Gene Mutation QED Therapeutics Inc. December 27 2019 Phase 3
NCT04131192 Recruiting Drug: Z650|Drug: Gemcitabine Pancreatic Cancer Sunshine Lake Pharma Co. Ltd. November 11 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What’s the difference between S1714 and S1149 and which one is better?

  • Answer:

    They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

selleck catalog

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

  • SCR7 New

    SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ). It increases the efficiency of HDR-mediated genome editing up to 19-fold using CRISPR/Cas9 in mammalian cells and mouse embryos.

  • Blasticidin S HCl New

    Blasticidin S HCl is a nucleoside antibiotic isolated from Stretomyces girseochromogenes, and acts as a DNA and protein synthesis inhibitor, used to select transfected cells carrying bsr or BSD resistance genes.

  • YK-4-279 New

    YK-4-279 is a potent inhibitor of EWS-FLI1 binding to RNA helicase A (RHA).

  • Cisplatin

    Cisplatin is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells. DMF is recommended, compared with DMSO.

    Features:One of the most widely used and most potent chemotherapeutic agents.

  • Oxaliplatin

    Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution.

  • Bleomycin Sulfate

    Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

  • Gemcitabine

    Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.

  • Fluorouracil (5-Fluorouracil, 5-FU)

    Fluorouracil (5-Fluorouracil, 5-FU) is a DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS) in tumor cells.

  • Carboplatin

    Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.

    Features:A DNA synthesis inhibitor.

  • Cytarabine

    Cytarabine is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells.

    Features:The 1st of a series of cancer drugs that alters the sugar component of nucleosides.

Tags: buy Gemcitabine HCl | Gemcitabine HCl supplier | purchase Gemcitabine HCl | Gemcitabine HCl cost | Gemcitabine HCl manufacturer | order Gemcitabine HCl | Gemcitabine HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID